Cetera Investment Advisers Acquires 603 Shares of Eli Lilly and Company (NYSE:LLY)

Cetera Investment Advisers lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,922 shares of the company’s stock after purchasing an additional 603 shares during the period. Cetera Investment Advisers’ holdings in Eli Lilly and Company were worth $203,641,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. J. W. Coons Advisors LLC increased its position in Eli Lilly and Company by 4.0% in the 4th quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after buying an additional 90 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Eli Lilly and Company by 27.9% during the fourth quarter. Jones Financial Companies Lllp now owns 9,024 shares of the company’s stock valued at $5,260,000 after acquiring an additional 1,967 shares in the last quarter. CWA Asset Management Group LLC increased its holdings in shares of Eli Lilly and Company by 32.7% during the fourth quarter. CWA Asset Management Group LLC now owns 3,272 shares of the company’s stock valued at $1,907,000 after acquiring an additional 807 shares in the last quarter. Belpointe Asset Management LLC raised its position in shares of Eli Lilly and Company by 3.5% during the fourth quarter. Belpointe Asset Management LLC now owns 5,175 shares of the company’s stock worth $3,017,000 after purchasing an additional 177 shares during the period. Finally, ROI Financial Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $9,181,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 52,369 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $915.18, for a total value of $47,927,061.42. Following the completion of the transaction, the insider now directly owns 97,247,403 shares of the company’s stock, valued at approximately $88,998,878,277.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 364,810 shares of company stock valued at $339,366,198 over the last quarter. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.9 %

LLY opened at $885.56 on Tuesday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company’s 50-day moving average price is $896.50 and its two-hundred day moving average price is $844.99. The stock has a market cap of $841.64 billion, a price-to-earnings ratio of 130.42, a PEG ratio of 2.78 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Barclays increased their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.